Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Per Odin

Showing results (91-100 of 170) with videos related to

Pageof 17
Sort By:
Expert Review of Neurotherapeutics|March 28, 2025
Managing impulse control and related behavioral disorders in Parkinson's disease: where we are in 2025?Leonardo Rigon, Carmelo Fogliano, K Ray Chaudhuri, et al.
Acta Neurologica Scandinavica|August 20, 2020
The Non-Motor Symptoms Scale in Parkinson's disease: Validation and useDaniel J van Wamelen, Pablo Martinez-Martin, Daniel Weintraub, et al.
Journal of Parkinson'S Disease|January 2, 2021
Cost-Effectiveness of Device-Aided Therapies in Parkinson's Disease: A Structured ReviewKatarzyna Smilowska, Daniel J van Wamelen, Tomasz Pietrzykowski, et al.
Scientific Reports|April 16, 2026
Foslevodopa-Foscarbidopa subcutaneous infusion in Parkinson's disease: a cross-cultural/cross-racial international multicentre comparative tolerability study (CRIM-FOS study)Vinod Metta, Karolina Poplawska-Domaszewicz, Ola Brek, et al.
Neurology|June 15, 2022
Pharmacokinetics of Intravenously (DIZ101), Subcutaneously (DIZ102), and Intestinally (LCIG) Infused Levodopa in Advanced Parkinson DiseaseFilip Bergquist, Mats Ehrnebo, Dag Nyholm, et al.
Translational Neurodegeneration|October 13, 2022
Why do 'OFF' periods still occur during continuous drug delivery in Parkinson's disease?Silvia Rota, Daniele Urso, Daniel J van Wamelen, et al.
NPJ Parkinson'S Disease|May 16, 2018
Viewpoint and practical recommendations from a movement disorder specialist panel on objective measurement in the clinical management of Parkinson's diseasePer Odin, K Ray Chaudhuri, Jens Volkmann, et al.
Journal of Neuroscience Research|September 26, 2007
Up-regulation of platelet-derived growth factor by peripheral-blood leukocytes during experimental allergic encephalomyelitisNiklas K U Koehler, Markus Roebbert, Kourosh Dehghani, et al.
Frontiers in Neurology|July 29, 2022
Objective Observer vs. Patient Motor State Assessments Using the PD Home Diary in Advanced Parkinson's DiseaseJonathan Timpka, Matthias Löhle, Alexander Bremer, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)|October 6, 2025
Effects of levodopa-entacapone-carbidopa intrajejunal infusion on non-motor symptoms of advanced Parkinson's disease-interim analysis of the ELEGANCE studyTobias Warnecke, Per Odin, Rocío García-Ramos, et al.
Pageof 17

Showing results (91-100 of 170) with videos related to

Sort By:
Pageof 17
Expert Review of Neurotherapeutics|March 28, 2025
Managing impulse control and related behavioral disorders in Parkinson's disease: where we are in 2025?Leonardo Rigon, Carmelo Fogliano, K Ray Chaudhuri, et al.
Acta Neurologica Scandinavica|August 20, 2020
The Non-Motor Symptoms Scale in Parkinson's disease: Validation and useDaniel J van Wamelen, Pablo Martinez-Martin, Daniel Weintraub, et al.
Journal of Parkinson'S Disease|January 2, 2021
Cost-Effectiveness of Device-Aided Therapies in Parkinson's Disease: A Structured ReviewKatarzyna Smilowska, Daniel J van Wamelen, Tomasz Pietrzykowski, et al.
Scientific Reports|April 16, 2026
Foslevodopa-Foscarbidopa subcutaneous infusion in Parkinson's disease: a cross-cultural/cross-racial international multicentre comparative tolerability study (CRIM-FOS study)Vinod Metta, Karolina Poplawska-Domaszewicz, Ola Brek, et al.
Neurology|June 15, 2022
Pharmacokinetics of Intravenously (DIZ101), Subcutaneously (DIZ102), and Intestinally (LCIG) Infused Levodopa in Advanced Parkinson DiseaseFilip Bergquist, Mats Ehrnebo, Dag Nyholm, et al.
Translational Neurodegeneration|October 13, 2022
Why do 'OFF' periods still occur during continuous drug delivery in Parkinson's disease?Silvia Rota, Daniele Urso, Daniel J van Wamelen, et al.
NPJ Parkinson'S Disease|May 16, 2018
Viewpoint and practical recommendations from a movement disorder specialist panel on objective measurement in the clinical management of Parkinson's diseasePer Odin, K Ray Chaudhuri, Jens Volkmann, et al.
Journal of Neuroscience Research|September 26, 2007
Up-regulation of platelet-derived growth factor by peripheral-blood leukocytes during experimental allergic encephalomyelitisNiklas K U Koehler, Markus Roebbert, Kourosh Dehghani, et al.
Frontiers in Neurology|July 29, 2022
Objective Observer vs. Patient Motor State Assessments Using the PD Home Diary in Advanced Parkinson's DiseaseJonathan Timpka, Matthias Löhle, Alexander Bremer, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)|October 6, 2025
Effects of levodopa-entacapone-carbidopa intrajejunal infusion on non-motor symptoms of advanced Parkinson's disease-interim analysis of the ELEGANCE studyTobias Warnecke, Per Odin, Rocío García-Ramos, et al.
Pageof 17